This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

AstraZeneca Framtida tillväxt

Future kriterier kontrolleras 2/6

AstraZeneca förväntas öka intäkter och intäkter med 13.2% respektive 6.1% per år. EPS förväntas tillväxt med 14.3% per år. Avkastningen på eget kapital förväntas bli 32.2% om 3 år.

Viktig information

13.2%

Tillväxttakt i vinsten

14.30%

Tillväxttakt för EPS

Pharmaceuticals vinsttillväxt	14.4%
Intäkternas tillväxttakt	6.1%
Framtida avkastning på eget kapital	32.20%
Bevakning av analytiker	Good
Senast uppdaterad	03 Feb 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

Seeking Alpha • Jan 10

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

Summary AstraZeneca started 2026 on a high note. On January 7, its stock reached an all-time high of $95.94. The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises. For example, sales of Tagrisso, an EGFR inhibitor for the treatment of people with non-small cell lung cancer, reached $1.86 billion in Q3, up 11.4% year-on-year. And coupledwith significant progress in its baxdrostat and blockbuster therapy Imfinzi, Icontinue to cover AstraZeneca with a 'Buy' rating. Read the full article on Seeking Alpha

Seeking Alpha • Mar 05

AstraZeneca: A Big Pharma Blue Chip To Buy Now

Summary AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. The company is well-positioned for growth over the next few years. AstraZeneca's net debt-to-adjusted EBITDA ratio improved to just 1.5x in 2024. Shares of the drugmaker appear to be priced 14% below fair value. AstraZeneca could be set up to generate 15% annual total returns through 2027. Read the full article on Seeking Alpha

Prognoser för vinst- och omsättningstillväxt

NasdaqGS:AZN - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
Datum	Intäkter	Intäkter	Fritt kassaflöde	Kassaflöde från rörelsen	Genomsnittligt Antal analytiker
12/31/2028	69,753	14,320	17,474	20,694	10
12/31/2027	65,894	13,694	14,299	18,813	23
12/31/2026	62,077	11,959	11,938	16,817	24
12/31/2025	58,546	10,133	8,397	14,457	24
9/30/2025	58,127	9,399	9,679	15,140	N/A
6/30/2025	56,501	8,295	8,327	13,389	N/A
3/31/2025	54,982	7,772	9,195	13,088	N/A
12/31/2024	54,073	7,035	7,398	11,861	N/A
9/30/2024	51,206	6,495	6,867	11,334	N/A
6/30/2024	49,133	6,440	7,045	11,065	N/A
3/31/2024	47,611	6,331	5,887	9,698	N/A
12/31/2023	45,811	5,955	6,858	10,345	N/A
9/30/2023	44,994	5,896	7,270	10,363	N/A
6/30/2023	44,485	6,163	6,854	10,179	N/A
3/31/2023	43,840	4,705	6,357	9,709	N/A
12/31/2022	44,351	3,288	7,684	9,808	N/A
9/30/2022	45,155	2,040	6,538	8,828	N/A
6/30/2022	44,038	-1,253	5,789	7,617	N/A
3/31/2022	41,487	-1,063	5,721	7,261	N/A
12/31/2021	37,417	112	4,350	5,963	N/A
9/30/2021	32,816	1,471	5,184	6,343	N/A
6/30/2021	29,528	3,771	5,421	6,446	N/A
3/31/2021	27,583	3,977	4,899	6,594	N/A
12/31/2020	26,617	3,196	3,144	4,799	N/A
9/30/2020	25,871	2,497	3,273	4,376	N/A
6/30/2020	25,699	2,148	3,057	3,657	N/A
3/31/2020	25,247	1,522	2,789	3,495	N/A
12/31/2019	24,384	1,335	2,585	2,969	N/A
9/30/2019	24,137	2,056	4,230	3,818	N/A
6/30/2019	23,071	2,188	N/A	3,184	N/A
3/31/2019	22,403	2,408	N/A	2,371	N/A
12/31/2018	22,090	2,155	N/A	2,618	N/A
9/30/2018	21,450	2,422	N/A	1,391	N/A
6/30/2018	22,342	2,677	N/A	3,165	N/A
3/31/2018	22,238	2,804	N/A	3,350	N/A
12/31/2017	22,465	3,001	N/A	3,578	N/A
9/30/2017	22,273	3,542	N/A	4,541	N/A
6/30/2017	21,740	3,870	N/A	3,109	N/A
3/31/2017	22,292	3,390	N/A	3,040	N/A
12/31/2016	23,002	3,499	N/A	4,145	N/A
9/30/2016	23,816	2,465	N/A	2,756	N/A
6/30/2016	24,062	2,221	N/A	3,690	N/A
3/31/2016	24,766	2,921	N/A	4,589	N/A
12/31/2015	24,708	2,825	N/A	3,324	N/A
9/30/2015	25,025	1,696	N/A	4,595	N/A
6/30/2015	25,689	1,180	N/A	4,800	N/A
3/31/2015	26,144	1,279	N/A	5,799	N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: AZN s prognostiserade vinsttillväxt ( 13.2% per år) är över sparkvoten ( 3.3% ).

Resultat vs marknad: AZN s intäkter ( 13.2% per år) förväntas växa långsammare än marknaden för US ( 16.8% per år).

Höga tillväxtresultat: AZN s intäkter förväntas växa, men inte avsevärt.

Intäkt vs marknad: AZN s intäkter ( 6.1% per år) förväntas växa långsammare än marknaden för US ( 11.6% per år).

Hög tillväxtintäkter: AZN s intäkter ( 6.1% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: AZN s avkastning på eget kapital förväntas bli hög om 3 år ( 32.2 %)

Upptäck tillväxtföretag

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/02/03 04:33
Aktiekurs vid dagens slut	2026/01/30 00:00
Intäkter	2025/09/30
Årlig intjäning	2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

AstraZeneca PLC bevakas av 60 analytiker. 24 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
null null	ABG Sundal Collier
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research

This company listing is no longer active

AstraZeneca Framtida tillväxt

Future kriterier kontrolleras 2/6

Viktig information

Senaste uppdateringarna om framtida tillväxt

AstraZeneca PLC Reiterates Earnings Guidance for 2025

AstraZeneca PLC Reiterates Earnings Guidance for the Fiscal Year 2025

Recent updates

AstraZeneca PLC (LSE:AZN) agreed to acquire remaining 50% stake in China rights to GPC3 armored CAR-T therapy from Abelzeta Inc. for $630 million.

European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

AstraZeneca PLC (LSE:AZN) acquired Modella AI, Inc.

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

AstraZeneca Appoints Rick R. Suarez As Senior Vice President, US President, And Head Of US BioPharmaceuticals Business Unit

Astrazeneca and Enhertu Announce that it has Been Granted Breakthrough Therapy Designation in the US for Adult Patients with Her2-Positive Early Breast Cancer with Residual Invasive Disease in the Breast And/Or Axillary Lymph Nodes After Neoadjuvant Treatment and High Risk of Disease Recurrence

Daiichi Sankyo and AstraZeneca's DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

Astrazeneca and Daiichi Sankyo's ENHERTU®? (Fam-Trastuzumab Deruxtecan-nxki) Approves in the US as First New Treatment in A decade for the 1st-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

AstraZeneca PLC Advances Hematology and Cell Therapy Ambition with Largest-Ever Presence at ASH

AstraZeneca's New Drug Application Accepted Under FDA Priority Review in the US for Patients with Hard-To-Control Hypertension

AstraZeneca plc Announces Approval in the US for First and Only Perioperative Immunotherapy for Patients with Early Gastric and Gastroesophageal Cancers

Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib) Approves in the US

AstraZeneca Announces Positive Full Results from the Bax24 Phase III Trial

AstraZeneca PLC Reiterates Earnings Guidance for 2025

DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Small Cell Lung Cancer

AstraZeneca PLC Announces Koselugo Approved in the EUfor Plexiform Neurofibromas in Adults with Neurofibromatosis Type 1

AstraZeneca and Amgen's Tezepelumab Approves in the European Union

Daiichi Sankyo and AstraZeneca Announces Positive Results from the TROPION-Breast02 Phase 3 Trial

AstraZeneca and Amgen's Tezepelumab Approves in the US for Chronic Rhinosinusitis with Nasal Polyps

AstraZeneca, Inc. Announces Positive Results from the Matterorn Phase III Trial

AstraZeneca Furthers ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO

AstraZeneca PLC Announces Baxdrostat Met Primary Endpoints in Bax24 Phase Iii Trial in Patients with Resistant Hypertension

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the TROPION-Breast02 Phase III Trial

Daiichi Sankyo and Astrazeneca's Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk Her2 Positive Early-Stage Breast Cancer Prior to Surgery

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from Planned Interim Analysis of the DESTINY-Breast05 Phase III Trial

AstraZeneca Launches Direct-To-Consumer Platform to Expand Access to Medications for US Patients, Including Those Living with Chronic Conditions

Daiichi Sankyo and AstraZeneca's Supplemental Biologics License Application for Enhertu®? in Combination with Pertuzumab Deruxtecan-nxki

AstraZeneca PLC Announces European Medicines Agency Recommends Koselugo for the Treatment of Plexiform Neurofibromas in Adult Patients

AstraZeneca, Inc. Provides Update on A Supplemental New Drug Application (sNDA) for Airscra

AstraZeneca plc Announces Saphnelo Met Primary Endpoint in TULIP-SC

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

AstraZeneca Announces Positive Results from the Final Overall Survival Analysis of the FLAURA2 Phase III Trial

AstraZeneca Launches FluMist Home, At-Home Delivery Service for FLUMIST

Astrazeneca Canada Inc. Announces Approval in Canada as First and Only Perioperative Immunotherapy for Muscle Invasive Bladder Cancer

AstraZeneca PLC Reiterates Earnings Guidance for the Fiscal Year 2025

AstraZeneca PLC Announces Positive Results from PrevaIL Phase III Trial

AstraZeneca Announces Positive High-Level Results from the Final Overall Survival Analysis of the FLAURA2 Phase III Trial

Alexion Announces Update on CARES Phase III Clinical Programme of Anselamimab in Light Chain Amyloidosis

AstraZeneca plc Announces Baxdrostat Met the Primary and All Secondary Endpoints in BaxHTN Phase III Trial in Patients with Undunded or Treatment Resistant Hypertension

European Union Approves Imfinzi®? (Durvalumab) for the Treatment of Adult Patients with Resistant Muscle-Invasive Bladder Cancer

Datroway Approves in Us for EGFRm Lung Cancer

AstraZeneca plc Announces Fixed-Term Calquence Approval in EU for 1L CLL

AstraZeneca and Daiichi Sankyo’S ENHERTU Plus Pertuzumab Showed A Median Progression-Free Survival Greater Than Three Years

Astrazeneca's Imfinzi Recommends for Approval in the Eu by Chmp as First and Only Perioperative Immunotherapy for Muscle-Invasive Bladder Cancer

Health Canada Grants Notice of Compliance with Conditions for Tagrisso (Osimertinib) for the Treatment of Patients with Locally Advanced, Unresectable (Stage Iii) Non-Small Cell Lung Cancer

AstraZeneca 's Record Seventh Year of Plenary Data At Asco Furthers Ambition to Redefine Breast Cancer Care and Transform Outcomes in Gastric Cancer

AstraZeneca PLC (LSE:AZN) completed the acquisition of EsoBiotec B.V.

Astrazeneca to Showcase Latest Research on Comprehensive Portfolio and Pipeline Aimed At Transforming Respiratory Diseases At ATS 2025

AstraZeneca’s IMFINZI® (durvalumab) Regimen Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival for High-Risk Non-Muscle-Invasive Bladder Cancer in Potomac Phase III Trial

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the DESTINY-Breast11 Phase III Trial

Astrazeneca Met Primary Endpoints in Kalos and Logos Phase Iii Trials in Asthma

AstraZeneca PLC to Report Q2, 2025 Results on Jul 29, 2025

Enhertu Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

AstraZeneca PLC Appoints Karen Knudsen as Director

Daiichi Sankyo and AstraZeneca Announce European Union Approves DATROWAY®? for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

AstraZeneca PLC Approves Imfinzi in Eu for AEGEAN

AstraZeneca’s AZD0780 Demonstrates Significant LDL Cholesterol (LDL-C) Reduction in Pursuit Phase IIb Trial

IgniteData Advances Clinical Trial Efficiencies with Successful Deployment at Leading Cancer Center

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

AstraZeneca PLC Announces Eneboparatide Met Primary Endpoint of Normalising Seric Calypso Trial Continues as Planned to 52 Weeks to Further Characterise the Risk-Benef Benefit Profile

Ionis Pharmaceuticals, Inc. and Astrazeneca’s WAINZUA (eplontersen) Approves in the EU for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy

AstraZeneca PLC Announces Positive High-Level Results from the Matterhorn Phase III Trial